Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Roberts KG, et al. Among authors: moore as. N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088. N Engl J Med. 2014. PMID: 25207766 Free PMC article.
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL. Sadras T, et al. Among authors: moore as, moore s. Cancer Lett. 2017 Nov 1;408:92-101. doi: 10.1016/j.canlet.2017.08.034. Epub 2017 Sep 1. Cancer Lett. 2017. PMID: 28866095
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment.
Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Pozza LD, Yeung DT, Sutton R, White DL. Heatley SL, et al. Among authors: moore as, moore s. Haematologica. 2017 Dec;102(12):e490-e493. doi: 10.3324/haematol.2016.162925. Epub 2017 Sep 21. Haematologica. 2017. PMID: 28935844 Free PMC article. No abstract available.
The genetic basis and cell of origin of mixed phenotype acute leukaemia.
Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, Buldini B, Basso G, Elitzur S, de Haas V, Zwaan CM, Yeoh A, Reinhardt D, Tomizawa D, Kiyokawa N, Lammens T, De Moerloose B, Catchpoole D, Hori H, Moorman A, Moore AS, Hrusak O, Meshinchi S, Orgel E, Devidas M, Borowitz M, Wood B, Heerema NA, Carrol A, Yang YL, Smith MA, Davidsen TM, Hermida LC, Gesuwan P, Marra MA, Ma Y, Mungall AJ, Moore RA, Jones SJM, Valentine M, Janke LJ, Rubnitz JE, Pui CH, Ding L, Liu Y, Zhang J, Nichols KE, Downing JR, Cao X, Shi L, Pounds S, Newman S, Pei D, Guidry Auvil JM, Gerhard DS, Hunger SP, Inaba H, Mullighan CG. Alexander TB, et al. Among authors: moore as, moore ra. Nature. 2018 Oct;562(7727):373-379. doi: 10.1038/s41586-018-0436-0. Epub 2018 Sep 12. Nature. 2018. PMID: 30209392 Free PMC article.
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.
Venn NC, Huang L, Hovorková L, Muskovic W, Wong M, Law T, Heatley SL, Khaw SL, Revesz T, Dalla Pozza L, Shaw PJ, Fraser C, Moore AS, Cross S, Bendak K, Norris MD, Henderson MJ, White DL, Cowley MJ, Trahair TN, Zuna J, Sutton R. Venn NC, et al. Among authors: moore as. Br J Cancer. 2022 Sep;127(5):908-915. doi: 10.1038/s41416-022-01806-6. Epub 2022 Jun 1. Br J Cancer. 2022. PMID: 35650277 Free PMC article.
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM. Smith AM, et al. Among authors: moore a. Oncotarget. 2016 Jul 26;7(30):47465-47478. doi: 10.18632/oncotarget.10167. Oncotarget. 2016. PMID: 27329844 Free PMC article.
EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
Charmsaz S, Al-Ejeh F, Yeadon TM, Miller KJ, Smith FM, Stringer BW, Moore AS, Lee FT, Cooper LT, Stylianou C, Yarranton GT, Woronicz J, Scott AM, Lackmann M, Boyd AW. Charmsaz S, et al. Among authors: moore as. Leukemia. 2017 Aug;31(8):1779-1787. doi: 10.1038/leu.2016.371. Epub 2016 Dec 6. Leukemia. 2017. PMID: 27922598
262 results